Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pretty new to this. Not sure how to read it. Appreciate any assistance. Don't need details more a big picture concept. Thanks!
You must know how to read charts.
It just shows the current trend of ENTA
What does this mean?
Earnings Per Share (EPS) = 1.14
Mavyret US scripts—week ending 11/3/17: #msg-136101015.
No news that I'm aware of.
Mavyret US scripts—week ending 10/27/17: #msg-135920382.
No—still searching for an explanation.
Dew did you ever come up with an acceptable conclusion for this sale?
ABBV reduces ENTA equity stake slightly: #msg-135761339.
Mavyret will have peak annual sales of “multi-billions,” says ABBV CEO, Rick Gonzales on today's 3Q17 CC.
Mavyret 3Q17 sales (partial quarter) ~$100M: #msg-135740870.
The EDP-305 phase-1/1b data are everything investors could have wanted at this stage, IMO.
The phase-2 trial in NASH patients, which begins in 2018, will be the first test of efficacy.
ENTA reports phase-1/1b data for EDP-305:
#msg-135609371
The phase-1 portion of the trial dosed healthy volunteers; the phase-1b portion of the trial dosed patients with presumed NAFLD, based on metabolic parameters.
Dew, any thoughts on the data? Or too early?
http://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-announces-positive-phase-1-ab-clinical
Caution: My 40% number represents patient share, not dollar share, so the numbers on the chart are not directly comparable.
Still, a 40% patient share ought to translate into a dollar share of more than 17%.
I saw it in an article recently but couldn't locate the article so I googled hep c charts and was able to find it.
Thanks. Where did you find that chart?
AASLD full-text presentations should be available at:
http://aasldpubs.onlinelibrary.wiley.com/hub/issue/10.1002/hep.v66.S1/
So is the data accessible? Or will it actually be presented Monday morning?
ENTA’s EDP-305 presentations at AASLD:
https://finance.yahoo.com/news/enanta-pharmaceuticals-present-preclinical-data-120200005.html
Yes, I think it does.
Doesn't that imply significant upside to ENTA, on that alone?
Mavyret should be able to get a 40% worldwide market share in due course (IMO). I don't know how my number compares to the consensus.
Mavyret scripts for week ending 10/13/17: #msg-135560245.
What's your low estimate guess on where market share will end up at compared to market (via enta sp) expectations? I know it is approximate but give it a shot.
(EDIT)You might be interested in AASLD abstract #205
I don't know what is permissible to post as pertains to embargo
Mavyret scripts for week ending 9/29/17: #msg-135250104.
FDA's Approval Of A Cheaper Drug For Hepatitis C Will Likely Expand Treatment- NPR
http://www.npr.org/sections/health-shots/2017/10/04/555156577/fdas-approval-of-a-cheaper-drug-for-hepatitis-c-will-likely-expand-treatment
Mavyret scripts for week ending 9/22/17: #msg-135002682.
That's not Barron's per se—it's a sell-side note from Maxim Group that Barron's picked up for one of its online trading blogs. We'll soon know if it's accurate.
http://www.barrons.com/articles/gileads-china-entrance-looks-crowded-1506532587
Seems to corroborate;
"As a reminder, Daklinza and Sunvepra, Bristol-Myers Squibb’s (BMY) dual-drug regimen was previously approved by the CFDA in April. It was the first direct-acting antiviral agents approved in China. In addition, Olysio (commercialized by Johnson & Johnson (JNJ)) was approved this past August, and AbbVie’s (ABBV) ombitasvir/dasabuvir, was approved on the same day as Sovaldi. We also note that the CFDA accepted Ascletis’ (a domestic Chinese specialty pharma company) Danoprevir application for approval in January and Merck’s (MRK) Zepatier application for approval in August."
============
I don't know how to prove this, short of calling ABBV or ENTA public relations. One would think Barrons is correct.
If it were so, by some mechanism I don't understand, the 3-D 1st gen program would have been approved in China before Harvoni.
In the USA Harvoni was approved 10-10-2014 and Viekira was december 2014; about 2 months later.
In the USA, Harvoni approval followed Sovaldi approval by about 10 months.
Main point is, if Abbvie was successful with the 1st gen program approval in China, could it also be true they may be adept with the 2nd gen Maviret?
Dew, I don't want to post bad info, but if this is....IF it were to be correct you'd want to know.
I agree that you would think there would be a release from ABBV or ENTA.
Here is the next thing...
If it is so that Viekira is now approved in China, ENTA should start seeing some increased revenue from the 1st gen when people are expecting it to decrease.
Feel free to delete if you feel this is in error
The SA piece is assuredly wrong about Viekira approval in China. ABBV and ENTA would have issued press releases for that.
Maviret in China?
So enta has had a great several months. This week the news is also looking good; approval in Japan and what seems to be encouraging updates (and data release at AASLD) on ENTA's FXR agonist, EDP-305.
Gilead also had good news with approval of Sovaldi in China which is a large market. (10 million HCV infected)
What are the prospects and timetable for Maviret?
BMY got in early; might Abbvie?
I can't speak to the accuracy of this, but if true, abbvie G/P approval could be earlier than market expects.
https://seekingalpha.com/article/4110203-gilead-spruces-large-target-market
"One of Gilead's bigger competitors in the Hepatitis C space, Abbvie (ABBV) saw approval for its drugs ombitasvir and dasabuvir the same time that Sovaldi was approved in China. "
(I almost doubt this; I wonder if the author meant Harvoni, not sovaldi- regardless the approvals may not roll out exactly in the same sequence and timetable as they were US and OUS)
No doubt both Gilead and Abbvie are are attempting to bring their HCV programs to approval ASAP.
It will be interesting to see how rapidly the current GILD and ABBV HCV programs are approved in China.
Many investors think that HCV is tapped out. I notice that the number of infected in the USA could still be higher than when sovaldi was first approved; partially due to uncertainty of estimates and partially due to the current opioid crisis.
IMHO there is a lot of market left, particularly for a pangenotypic 8 week program.
I have to wonder if both GILD and Abbvie programs will see very rapid approvals.
Any way to estimate approvals times?
ENTA’s AASLD presentations for EDP-305 (NASH/PBC):
https://www.businesswire.com/news/home/20170927006300/en
Japan approves Maviret, triggering $15M milestone payment: #msg-134935488.
Mavyret scripts for week ending 9/18/17: #msg-134887306.
New slide set from CF presentation today:
http://ir.enanta.com/static-files/6260935a-3ef6-4854-ac8e-03595d82bfa9
Highest intraday and closing prices since Aug2015 (eom).
Mavyret scripts for week ending 9/8/17 (from IMS)…
TRx: 185, +29% from prior week
NRx: 156, +14% from prior week
Note: Mavyret’s absolute script figures reported by IMS are low because IMS misses much of the public sector of the HCV market that ABBV is targeting.
Yes, I erroneously switched the numbers—will repost. Thanks for noticing!
RBC Capital initiates coverage on Enanta Pharmaceuticals (NASDAQ: ENTA) with a Outperform rating and a price target of $54.00.
Followers
|
98
|
Posters
|
|
Posts (Today)
|
2
|
Posts (Total)
|
3314
|
Created
|
03/20/13
|
Type
|
Free
|
Moderators DewDiligence |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |